Intuitive Surgical Robot Incident Reports Double in Year

Intuitive Surgical Robot Incident Reports Double in Year

The number of adverse incident reports involving Intuitive Surgical Inc.’s (ISRG) robots more than doubled this year, according to U.S. regulators who also released a physician survey showing no consistent training exists for the complex machines. The Food and Drug Administration received 3,697 adverse reports through Nov. 3, compared with 1,595 in 2012. The surge, though, doesn’t necessarily mean the rate has changed, said William Maisel, with the FDA’s device unit. Rising robot use and recent media reports and recalls may have spurred public attention, he said. The reports, from the company and medical professionals, are largely unverified by the agency.The FDA survey released yesterday included 11 doctors who have performed from 70 to 600 robot surgeries each. While they said the device led to fewer complications and shorter recoveries, they reported incidents in which robot arms collided or missed their mark and said training was an issue. The FDA didn’t draw conclusions on the device because of the survey size.

“All respondents report that learning how to use the da Vinci Surgical System is the biggest challenge because of the device’s complex user-interface,” the FDA said in a report on the survey, which reveals a wide variety of training experiences for doctors in four different specialties.

The 11 doctors surveyed also reported diverse patient complications, including reversible limb palsy, temporary nerve damage in the fingers, bleeding from perforated bowels and peripheral vision loss.

‘Positive Observations’

“While we are pleased with the surveyed surgeons’ very positive observations about the benefits of robotic surgery, this small informal survey cannot serve as the basis for any scientifically valid conclusions,” Angela Wonson, a spokeswoman for Sunnyvale, California-based Intuitive, said in a statement. “Large clinical studies have documented the comparative benefits of robotic surgery.”

Added training is available for surgeons who request it, Wonson said, “in many forms — from the manufacturer, from their hospital and from surgical societies.” Referring to comments that some doctors weren’t generally aware of recalls, she said they may not have been using the precise products recalled at a given time.

Intuitive has faced scrutiny this year over the marketing, cost effectiveness and safety of its robots, which cost $1.5 million apiece. In July, the company received an FDA warning letter after an inspection found it hadn’t adequately reported adverse events and device corrections. It also faces about 50 liability lawsuits from patients who allege injuries tied to the robot.

Marketing Effort

Bloomberg News reported last month that the rising use of robotic surgery has largely been fueled by aggressive marketing tactics by doctors and hospitals that gain a competitive edge from the use of the robots.

This includes widespread advertising that, in some cases, inflated the advantages of the robots by claiming fewer complications without proof and ignored broad-based contradictory studies finding little or no advantage to their use over similar non-invasive surgery.

Since Bloomberg News first reported in February on the existence of the FDA survey, the company’s shares have fallen 32 percent. On Oct. 17, Intuitive reported a decline in third-quarter profit as a result of lower sales. The company gained 2.7 percent to $389.83 at the close yesterday in New York.

In robot-assisted surgery, a physician sits at a video-game-style console several feet from the patient and peers into a high-definition display. Foot pedals and hand controls move mechanical arms equipped with tools, guided by a 3-D camera that shows the work as it is done inside a patient.

Injuries, Deaths

The FDA incident reports related to Intuitive’s robotic surgical system include injuries and deaths linked to robotic surgery operations, as well as malfunctions where no injury occurred. The agency first began looking at adverse events associated with the robots in 2011, when there were just 511 reports, said Maisel, the chief scientist for the FDA’s Center for Devices and Radiological Health.

“We identified issues that warranted additional investigation, and that prompted us to go out to the company and inspect them,” Maisel said in a telephone interview. The agency will continue to monitor the reports, he said.

Few Conclusions

“No one should be concluding simply from the increase in adverse event reports that there is a problem with the device and it should not be used,” Maisel said, adding the agency doesn’t have information suggesting the rate of robotic surgery adverse events is increasing.

Wonson, Intuitive’s spokeswoman, said “while the absolute number of adverse events have increased with the growth of procedures, the total adverse event rates have remained low and in line with historical trends.”

The surgeons surveyed by the FDA suggested doctors need time to learn how to use the foot pedals and perform operations. Two urologists said patient safety was “directly related to the surgeon’s training experience,” according to the FDA report.

All but one of the surgeons surveyed reported having trouble with the robot’s arms, which sometimes had to be repaired or replaced. Only three were aware of recalls related to the device.

Robot operations haven’t been proven in randomized trials to offer significant health benefits compared with standard, less-invasive surgery and multiple studies show they can cost thousands of dollars more. A study released in September of 16,000 women in the journal Obstetrics & Gynecology found that using the system for hysterectomies in woman with benign conditions didn’t reduce complications compared with conventional less-invasive techniques.

Hysterectomy Use

In gynecology, the doctors told the FDA the da Vinci system is particularly well suited for hysterectomies for patients with cancer or for uterus-preserving surgery to remove benign growths called fibroids. The urologists surveyed said the system was a good fit for prostate surgery and adrenal gland removal, and less well suited for kidney removal surgery, according to the FDA report.

Intuitive’s robotic surgery system was first cleared by the FDA for use in the U.S. in 2000 after a trial on 233 patients, done at a hospital in Mexico City. The 1998 trial compared robotic surgery in 113 patients with conventional operations for removing the gall bladder or treating heartburn. The study found no advantage for robotics, FDA officials told an advisory panel at an agency hearing in 1999.

To contact the reporter on this story: Robert Langreth in New York at

About bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (, the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: